Open AccessThe Role of Regulatory T Lymphocytes in Immune Control of MC-2 Fibrosarcoma
Author(s) -
Tomislav Jukić,
Ana Jurin Martić,
Siniša Ivanković,
Mariastefania Antica,
Doroteja Pavan Jukić,
Cecilija Rotim,
Mislav Jurin
Publication year - 2020
Publication title -
acta clinica croatica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.274
H-Index - 20
eISSN - 1333-9451
pISSN - 0353-9466
DOI - 10.20471/acc.2020.59.02.20
Subject(s) - splenocyte , fibrosarcoma , cd8 , transplantation , in vivo , monoclonal antibody , immune system , il 2 receptor , immunology , in vitro , cancer research , immunity , antibody , medicine , biology , t cell , pathology , biochemistry , microbiology and biotechnology
The role of T regulatory lymphocytes (T reg ) particularly in cancer is well known. The goal of the present study was to determine the contribution of these lymphocytes in the regulation of anti-tumor immunity of CBA/HZgr mice against MC-2 fibrosarcoma (4 th generation of methylcholanthrene induced tumor). The levels of T lymphocytes (CD4+, CD8+ and CD4+CD25+) were determined 8 and 20 days after tumor transplantation. Further, the role of CD4+CD25+ (T regs ) in tumor-host interaction was evaluated in vitro and in vivo by using specific monoclonal antibodies. We found that splenocytes of both control and T reg depleted tumor bearing mice strongly but differently inhibited growth of tumor cells in vitro . While splenocytes of untreated mice exhibited significant decrease of this activity (from 74.4% to 62.6% and 32.95%), the splenocytes of T reg depleted mice showed increase of this activity (from 79.5% to 84.3% and 86.2%) from day 6 to day 13 and day 21 after tumor grafting, respectively. Further, upon i.v. injecting specific monoclonal anti-T reg antibody tumor immediately prior to tumor cell intracutaneous transplantation, the tumor was rejected after initial growth. In treated mice, the incidence of T reg cells was very low initially, reaching normal values two weeks later. These animals were shown to be resistant to tumor transplantation four months later.